论文部分内容阅读
目的:探讨人乳腺癌新辅助化疗前后MCM5和Ki-67蛋白的表达状况,分析其与化疗疗效关系的意义。方法:采用免疫组化法检测40例乳腺癌新辅助化疗前后标本中MCM5和Ki-67的表达。结果:新辅助化疗有效率为77.5%。化疗前MCM5和Ki-67蛋白阳性表达显著高于化疗后(P<0.01);化疗前MCM5蛋白阳性表达显著高于Ki-67(P<0.01)。化疗有效组(31例)。MCM5蛋白阳性表达显著高于无效组(9例)(P<0.01);化疗有效组Ki-67蛋白阳性表达高于无效组,但差异无显著性(P>0.05)。化疗前MCM5、Ki-67表达呈正相关(r=0.601,P<0.01)。结论:ET方案新辅助化疗有较好的疗效,可能通过抑制MCM5、Ki-67蛋白的表达来阻止乳腺癌细胞的增殖。MCM5蛋白高表达者化疗更为敏感,MCM5可作为临床指导乳腺癌化疗并预测化疗敏感性的分子生物学指标之一。
Objective: To investigate the expression of MCM5 and Ki-67 protein in human breast cancer before and after neoadjuvant chemotherapy, and to analyze the significance of the relationship between them and the curative effect of chemotherapy. Methods: Immunohistochemistry was used to detect the expression of MCM5 and Ki-67 in 40 cases of breast cancer before and after neoadjuvant chemotherapy. Results: The neoadjuvant chemotherapy rate was 77.5%. The positive expression of MCM5 and Ki-67 protein before chemotherapy was significantly higher than that after chemotherapy (P <0.01). The positive expression of MCM5 protein before chemotherapy was significantly higher than that of Ki-67 (P <0.01). Chemotherapy effective group (31 cases). The positive expression of MCM5 protein in the chemotherapy group was significantly higher than that in the ineffective group (9 cases) (P <0.01). The Ki-67 protein expression in the chemotherapy-effective group was higher than that in the ineffective group (P> 0.05). Before chemotherapy, the expression of MCM5 and Ki-67 were positively correlated (r = 0.601, P <0.01). Conclusion: Neonadjuvant chemotherapy with ET has good curative effect, which may prevent the proliferation of breast cancer cells by inhibiting the expression of MCM5 and Ki-67 protein. MCM5 protein high expression chemotherapy is more sensitive, MCM5 can be used as clinical molecular markers of breast cancer chemotherapy and predict chemosensitivity.